Rune Oskar Bjørnekletts bilde

Rune Oskar Bjørneklett

  • E-postrune.bjorneklett@uib.no
  • Besøksadresse
    Nyreseksjonen, Medisinsk Avdeling, Haukeland Universitetsjukehus
  • Postadresse
    Postboks 7804
    5020 Bergen

Ansvarlig for undervisning i nefrologi.

Vitenskapelig artikkel
  • Vis forfatter(e) (2024). Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study. BMC Nephrology. 42.
  • Vis forfatter(e) (2024). Microbial aetiology of community-acquired pneumonia in hospitalised adults: A prospective study utilising comprehensive molecular testing. International Journal of Infectious Diseases.
  • Vis forfatter(e) (2024). Epstein-Barr in a Patient Presenting with Right Upper Quadrant Pain: A Case Report from the Emergency Department. Journal of Emergency Medicine. e365-e368.
  • Vis forfatter(e) (2024). Diagnostic Stewardship in Community-Acquired Pneumonia with Syndromic Molecular Testing: A Randomized Clinical Trial. JAMA Network Open. E240830.
  • Vis forfatter(e) (2023). Validation of a modified South African triage scale in a high-resource setting: a retrospective cohort study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.
  • Vis forfatter(e) (2023). The diagnostic utility of microscopic quality assessment of sputum samples in the era of rapid syndromic PCR testing. Microbiology spectrum.
  • Vis forfatter(e) (2023). Prognostic value of growth differentiation factor-15 3 months after an acute chest pain admission. Heart. 9 sider.
  • Vis forfatter(e) (2023). Prognostic significance of chronic myocardial injury diagnosed by three different cardiac troponin assays in patients admitted with suspected acute coronary syndrome. Clinical Chemistry and Laboratory Medicine. 729-739.
  • Vis forfatter(e) (2023). Long-term follow-up of IgA nephropathy: clinicopathological features and predictors of outcomes. Clinical Kidney Journal (CKJ). 2514-2522.
  • Vis forfatter(e) (2023). Growth Differentiation Factor 15: A Prognostic Marker in Patients with Acute Chest Pain without Acute Myocardial Infarction. Clinical Chemistry. 649-660.
  • Vis forfatter(e) (2023). Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy. Kidney International. 717-730.
  • Vis forfatter(e) (2023). Diagnostic utility of oropharyngeal swabs as an alternative to lower respiratory tract samples for PCR-based syndromic testing in patients with community-acquired pneumonia. Journal of Clinical Microbiology. 11 sider.
  • Vis forfatter(e) (2022). Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up. Nephrology, Dialysis and Transplantation. 1183-1191.
  • Vis forfatter(e) (2022). Utilizing the MEST score for prognostic staging in IgA nephropathy. BMC Nephrology. 1-11.
  • Vis forfatter(e) (2022). The changing spectrum of microbial aetiology of respiratory tract infections in hospitalized patients before and during the COVID-19 pandemic. BMC Infectious Diseases. 1-11.
  • Vis forfatter(e) (2022). Rapid syndromic PCR testing in patients with respiratory tract infections reduces time to results and improves microbial yield. Scientific Reports.
  • Vis forfatter(e) (2022). Predictors of long-term symptom burden and quality of life in patients hospitalised with chest pain: a prospective observational study. BMJ Open. 1-10.
  • Vis forfatter(e) (2022). Implementing a new emergency medical triage tool in one health region in Norway: some lessons learned. BMJ Open Quality.
  • Vis forfatter(e) (2022). Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR). Trials.
  • Vis forfatter(e) (2022). Comparison of rapid molecular testing methods for detecting respiratory viruses in emergency care: a prospective study. Infectious Diseases. 247-254.
  • Vis forfatter(e) (2022). Association between symptoms and risk of non-ST segment elevation myocardial infarction according to age and sex in patients admitted to the emergency department with suspected acute coronary syndrome: a single-centre retrospective cohort study. BMJ Open. 1-12.
  • Vis forfatter(e) (2022). Adding stress biomarkers to high-sensitivity cardiac troponin for rapid non-ST-elevation myocardial infarction rule-out protocols. European Heart Journal: Acute Cardiovascular Care. 201-212.
  • Vis forfatter(e) (2021). Diagnostic performance of novel troponin algorithms for the rule-out of non-ST-elevation acute coronary syndrome. Clinical Chemistry. 291-302.
  • Vis forfatter(e) (2021). Clinical risk scores identify more patients at risk for cardiovascular events within 30 days as compared to standard ACS risk criteria: The WESTCOR study. European Heart Journal: Acute Cardiovascular Care. 287-301.
  • Vis forfatter(e) (2020). Hypertensive nephrosclerosis: wider kidney biopsy indications may be needed to improve diagnostics. Journal of Internal Medicine. 1-15.
  • Vis forfatter(e) (2020). Clinical phenotypes and long-term prognosis in white patients with biopsy-verified hypertensive nephrosclerosis. Kidney International Reports. 339-347.
  • Vis forfatter(e) (2020). Cardiac Troponin Assays With Improved Analytical Quality: A Trade‐Off Between Enhanced Diagnostic Performance and Reduced Long‐Term Prognostic Value. Journal of the American Heart Association (JAHA). 23 sider.
  • Vis forfatter(e) (2019). Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrology, Dialysis and Transplantation. 301-308.
  • Vis forfatter(e) (2019). Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain-the WESTCOR study: study design. Scandinavian Cardiovascular Journal. 280-285.
  • Vis forfatter(e) (2018). Prognostic factors in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with severe glomerular sclerosis: a national registry-based cohort study. Pathology Research International. 1-7.
  • Vis forfatter(e) (2018). Prognosis and Histological Classification in Elderly Patients with ANCA-Glomerulonephritis: A Registry-Based Cohort Study. BioMed Research International. 8 sider.
  • Vis forfatter(e) (2018). Impact of proteinase 3 versus myeloperoxidase positivity on risk of end-stage renal disease in ANCA-associated glomerulonephritis stratified by histological classification: A population-based cohort study. Disease Markers. 1-7.
  • Vis forfatter(e) (2018). Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study. International Urology and Nephrology. 1311-1318.
  • Vis forfatter(e) (2017). Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. Lupus. 881-885.
  • Vis forfatter(e) (2017). Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrology, Dialysis and Transplantation. 1841-1850.
  • Vis forfatter(e) (2017). Cancer in ANCA-associated glomerulonephritis: a registry-based cohort study. International Journal of Nephrology. 1-8.
  • Vis forfatter(e) (2016). Prognostic value of histologic classification of ANCA-associated glomerulonephritis. American Society of Nephrology. Clinical Journal. 2159-2167.
  • Vis forfatter(e) (2016). Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrology, Dialysis and Transplantation. 80-86.
  • Vis forfatter(e) (2015). Patient classification and outcome prediction in IgA nephropathy. Computers in Biology and Medicine. 278-286.
  • Vis forfatter(e) (2015). Addition of eGFR and age improves the prognostic absolute renal risk-model in 1,134 norwegian patients with IgA nephropathy. American Journal of Nephrology. 210-219.
  • Vis forfatter(e) (2014). Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies. Nephrology, Dialysis and Transplantation. i67-i75.
  • Vis forfatter(e) (2013). Mortality in patients with IgA nephropathy. American Journal of Kidney Diseases. 883-890.
  • Vis forfatter(e) (2012). Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort. Nephrology, Dialysis and Transplantation. 1485-1491.
  • Vis forfatter(e) (2011). Pre-transplant course and risk of kidney transplant failure in IgA nephropathy patients. Clinical Transplantation. E356-E365.
  • Vis forfatter(e) (2009). Belatacept as Immunosuppression in Patient With Recurrence of Hemolytic Uremic Syndrome After Renal Transplantation. Transplantation. 1901-1903.
  • Vis forfatter(e) (2007). Long-term risk of cancer in membranous nephropathy patients. American Journal of Kidney Diseases. 396-403.
  • Vis forfatter(e) (2018). ANCA-associated glomerulonephritis. Prognostic factors and outcome in a Norwegian cohort.
  • Vis forfatter(e) (2017). Prognostic aspects of IgA nephropathy.
  • Vis forfatter(e) (2012). Long-term prognosis in chronic primary glomerulonephritides.
  • Vis forfatter(e) (2012). VALIDATION OF FRENCH MODEL TO PREDICT ESRD AND DEATH IN IGA NEPHROPATHY PATIENTS. Nephrology, Dialysis and Transplantation. 189-190.
  • Vis forfatter(e) (2012). STANDARDIZED MORTALITY RATE IN IGA NEPHROPATHY PATIENTS. Nephrology, Dialysis and Transplantation. 188-188.
  • Vis forfatter(e) (2023). Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain using Point of Care Testing (WESTCOR- POC): study design. Scandinavian Cardiovascular Journal.

Se fullstendig oversikt over publikasjoner i CRIStin.